See more : Atlas Technical Consultants, Inc. (ATCX) Income Statement Analysis – Financial Results
Complete financial analysis of Hua Medicine (Shanghai) Ltd. (HUMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hua Medicine (Shanghai) Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Helios and Matheson Analytics Inc. (HMNY) Income Statement Analysis – Financial Results
- Hargreaves Services Plc (HSP.L) Income Statement Analysis – Financial Results
- Silicon Integrated Systems Corp. (2363.TW) Income Statement Analysis – Financial Results
- China Pacific Insurance (Group) Co., Ltd. (601601.SS) Income Statement Analysis – Financial Results
- Copenhagen Capital A/S (CPHCAP-PREF32.CO) Income Statement Analysis – Financial Results
Hua Medicine (Shanghai) Ltd. (HUMDF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.huamedicine.com
About Hua Medicine (Shanghai) Ltd.
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 76.61M | 17.60M | 0.00 | 8.66M | 22.26M | 9.13M | 10.52M | 595.00K |
| Cost of Revenue | 39.24M | 9.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 37.37M | 7.69M | 0.00 | 8.66M | 22.26M | 9.13M | 10.52M | 595.00K |
| Gross Profit Ratio | 48.78% | 43.69% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 171.54M | 129.53M | 186.84M | 220.96M | 321.90M | 269.07M | 125.34M | 75.27M |
| General & Administrative | 124.15M | 129.93M | 134.84M | 140.08M | 146.58M | 139.32M | 31.09M | 19.48M |
| Selling & Marketing | 79.76M | 15.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 203.90M | 145.28M | 134.84M | 140.08M | 146.58M | 139.32M | 31.09M | 19.48M |
| Other Expenses | -338.07M | -26.45M | -6.49M | -8.66M | -22.26M | -3.27B | -126.48M | -274.42M |
| Operating Expenses | 37.37M | 248.36M | 315.18M | 352.38M | 446.23M | 399.25M | 145.91M | 94.16M |
| Cost & Expenses | 414.68M | 258.27M | 315.18M | 352.38M | 446.23M | 399.25M | 145.91M | 94.16M |
| Interest Income | 16.51M | 4.24M | 5.04M | 4.37M | 7.32M | 1.23M | 1.19M | 435.00K |
| Interest Expense | 7.91M | 3.67M | 3.95M | 4.40M | 907.00K | 3.53M | 2.96M | 4.56M |
| Depreciation & Amortization | 36.24M | 31.78M | 11.98M | 4.95M | 3.36M | 1.53M | 637.00K | 361.00K |
| EBITDA | -167.09M | -168.06M | -309.69M | -347.43M | -442.87M | -358.80M | -145.27M | -93.40M |
| EBITDA Ratio | -218.10% | -953.49% | 0.00% | -4,286.60% | -1,852.03% | -39,425.73% | -2,652.19% | -60,244.71% |
| Operating Income | -289.09M | -199.58M | -320.52M | -389.84M | -422.64M | -399.25M | -145.91M | -94.16M |
| Operating Income Ratio | -377.36% | -1,134.05% | 0.00% | -4,499.53% | -1,898.90% | -4,373.45% | -1,387.62% | -15,825.04% |
| Total Other Income/Expenses | 77.86M | -3.93M | -4.06M | -40.75M | 20.96M | -3.24B | -134.78M | -268.25M |
| Income Before Tax | -211.23M | -203.51M | -325.73M | -393.13M | -425.27M | -3.60B | -280.69M | -362.41M |
| Income Before Tax Ratio | -275.73% | -1,156.36% | 0.00% | -4,537.56% | -1,910.72% | -39,478.56% | -2,669.41% | -60,908.91% |
| Income Tax Expense | 0.00 | 259.00K | 5.22M | 3.30M | 2.63M | -3.20B | -141.58M | -265.74M |
| Net Income | -211.23M | -203.77M | -330.95M | -396.43M | -427.90M | -3.60B | -272.71M | -361.33M |
| Net Income Ratio | -275.73% | -1,157.83% | 0.00% | -4,575.59% | -1,922.55% | -39,464.63% | -2,593.57% | -60,727.39% |
| EPS | -0.22 | -0.21 | -0.35 | -0.42 | -0.45 | -10.07 | -0.26 | -0.34 |
| EPS Diluted | -0.22 | -0.21 | -0.35 | -0.42 | -0.45 | -10.07 | -0.26 | -0.34 |
| Weighted Avg Shares Out | 977.06M | 966.73M | 957.49M | 950.51M | 942.06M | 357.86M | 1.05B | 1.05B |
| Weighted Avg Shares Out (Dil) | 977.05M | 966.73M | 957.49M | 950.51M | 942.06M | 357.86M | 1.05B | 1.05B |
Source: https://incomestatements.info
Category: Stock Reports